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rTo the Editor: Post-operative atrial fibrillation (PoAF) is among
the most common complications of cardiac surgery and substan-
tially increases morbidity and healthcare costs. Despite decades of
surgical, anesthetic, and medical advances, rates of PoAF remain
largely unchanged. Experiments and animal models suggest that
perioperative fish oil (omega-3 fatty acids) may reduce PoAF (1).
We recently reported in a large, multinational randomized trial
that perioperative fish oil did not reduce PoAF (2). Yet several
other trials have evaluated this question, with mixed results. Most
of these trials were small, and some were open label (i.e., neither
double blind nor placebo controlled).
To compile all peer-reviewed evidence and evaluate reasons
for potential heterogeneity, we conducted a meta-analysis,
following Preferred Reporting Items for Systemic Reviews and
Meta-Analyses guidelines, of randomized trials of fish oil for
preventing PoAF. We searched MEDLINE from earliest available
indexing throughOctober 2012, without language restrictions. Search
terms were (“fatty acids, omega-3”[MeSH] or “eicosapentaenoic
acid”[MeSH/tiab] or “docosahexaenoic acids”[MeSH/tiab] or
“fish oils”[MeSH] or “omega-3”[tiab] or “n-3”[tiab] or “long chain
n-3”[tiab] or “fish oil”[tiab]) and (“atrial fibrillation”[MeSH/tiab])
and (“clinical trial”[MeSH/tiab] or “cardiac surgical procedures-
”[MeSH/tiab]). Additional studies were identified by hand search-
ing citation lists and directly contacting experts. Studies were
included if they were randomized trials of oral or intravenous fish
oil administration that evaluated PoAF after cardiac surgery; trials
with additional concomitant interventions, observational studies,
and duplicate publications were excluded. Inclusion and exclusion
decisions and data extraction were performed in duplicate by 2 investi-
gators. Findings were pooled using inverse-varianceweighted meta-
analysis (3). Fixed-effects models were pre-specified on the basis of large
differences in sample sizes and results across studies, for which random-
effects models could dramatically overweight small, imprecise studies.
Pre-specified potential sources of heterogeneity included placebo control
(yes or no) and type of surgery (valve surgery, yes or no).
Of 83 identified abstracts, 8 full-text articles were retrieved for
review. Eight randomized trials met the inclusion criteria, includ-
ing 2,687 subjects and 859 PoAF events (Fig. 1). Heterogeneity
was evident (I2  52%, Q  14.5, p for heterogeneity  0.04),
principally owing to extreme results in 2 small, open-label (no
placebo) studies. The presence or absence of placebo control
significantly modified the effect of fish oil on PoAF (p for
interaction  0.028): benefits were seen in open-label, but not
placebo-controlled, trials. Also, a preponderance of small trials
with risk estimates below the pooled estimate suggested potential
publication bias toward small positive trials. Little heterogeneity
was evident among placebo-controlled trials (I2  16%, Q  5.9,
for heterogeneity  0.31), which both individually and together
emonstrated no significant effect (pooled odds ratio [OR]: 0.92;
5% confidence interval [CI]: 0.78 to 1.10). In sensitivity analyses, Iwe removed each trial individually from the pooled meta-analysis.
Finding were similar; for example, removing the large OPERA
(Omega-3 Fatty Acids for Prevention of Post-Operative Atrial
Fibrillation) trial, the pooled OR in the remaining placebo-
controlled trials was 0.86 (95% CI: 0.65 to 1.15; I2  28%, Q 
5.6). We note that only 2 open-label trials were identified, so
generalizability of these findings to other research questions should
not be assumed. Yet the variation in findings of small and
especially open-label studies highlights the importance of large,
adequately powered, placebo-controlled trials as well as appropri-
ately performed meta-analyses such as the present study.
In the large OPERA trial, subgroup analyses suggested a
potential benefit of fish oil treatment in patients undergoing valve
surgery (p for interaction 0.06) (2). We pooled these results with
those from 4 other placebo-controlled trials that provided data
stratified by type of cardiac surgery. In sum, data were available on
856 patients who underwent valve surgery and experienced 336
PoAF events and 1,249 patients not undergoing valve surgery who
experienced 358 PoAF events. Pooling all data, the effects of fish
oil on PoAF did not significantly differ according to valve surgery
(p for interaction 0.94): the OR was 0.91 (95% CI: 0.76 to 1.09)
in patients undergoing valve surgery and 1.00 (95% CI: 0.78 to
1.28) in patients not undergoing valve surgery. Dosing and
duration of fish oil treatment were generally similar among trials,
limiting the ability to explore heterogeneity by these factors.
We evaluated pooled evidence for safety, including numbers of
patients with major bleeding, total mortality, and other reported
serious adverse events. Fish oil was associated with less bleeding
(n  165 events, data reported in 5 trials: OR: 0.76; 95% CI: 0.60
to 0.96; I2  34.1, Q  6.1, p for heterogeneity  0.19), a
nonsignificant trend toward lower mortality (n  32 events, data
reported in 6 trials: OR: 0.68; 95% CI: 0.32 to 1.41; I2 0%, Q
1.98, p for heterogeneity  0.58), and no difference in other
reported serious adverse events (n  528 events, data reported in
6 trials: OR: 1.0; 95% CI: 0.81 to 1.25; I2  0%, Q  4.7, p for
eterogeneity  0.45) The unexpectedly lower bleeding risk could
e due to chance. Conversely, this observation could plausibly
elate to lower cardiopulmonary bypass–induced activation and loss
f platelets and clotting factors (4); further investigation of
otential mechanisms is required. At the least, the observed lower
leeding risk counters concerns that antiplatelet effects of fish oil
ight increase blood loss during cardiac surgery. Overall, the
ndings indicate that perioperative fish oil use was well tolerated
nd safe, suggesting little need for its discontinuation in patients
ho are taking fish oil before cardiac surgery.
In sum, our meta-analysis provides convincing evidence that
hort-term fish oil use does not appreciably reduce PoAF and
ndicates that heterogeneity in prior findings results from extreme
esults of small, open-label trials as well as potential publication bias.
n addition, we found little evidence for differing efficacy according to
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May 28, 2013:2194–8type of cardiac surgery. There is also little evidence that intermediate-
term (1 year) fish oil use reduces recurrent arrhythmias in patients
with established atrial fibrillation (5). Fish oil may still prove useful in
ther clinical contexts, such as long-term use (years) for preventing the
nitial onset of atrial fibrillation among ambulatory elderly adults with
ypertension or other risk factors. Such primary, rather than second-
ry, prevention approaches must be tested in large, appropriately
owered, placebo-controlled clinical trials.
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Letters to the Editor
Improving Quality
of Life and Functional
Capacity in Atrial Fibrillation
and Congestive Heart Failure
We read with interest the paper by Suman-Horduna et al. (1)
published in the January 2013 issue of the Journal. The investiga-
tors analyzed important quality-of-life data from a substantial
substudy (n  749) of a landmark trial (2), comparing rate control
to rhythm control for patients with paroxysmal (30%) or persis-
tent atrial fibrillation (AF) and congestive heart failure (CHF).Overall, each strategy was associated with similar improvements in
symptoms and quality of life, but results were confounded by the
high proportion of patients with paroxysmal AF (29.6%) assigned
to rate control who remained in sinus rhythm (i.e., crossed over to
rhythm control) and by patients assigned to rhythm control who
remained in AF (22.4%) (i.e., in whom rhythm control failed).
We previously conducted a small, randomized study exclusively
of patients with persistent AF and CHF (3), and encountered
similar problems in maintaining sinus rhythm but with no spon-
taneous return to sinus rhythm in those assigned to rate control;
therefore, we had a much lower rate of cross over than in the
AF-CHF trial. We found significant improvements in quality of
life, left ventricular function, and N-terminal pro–brain natriuretic
peptide concentrations overall, which benefited those in whom
sinus rhythm was restored and maintained during follow-up. The
6-min walk test distance also improved for patients in whom a
rhythm control strategy was successful.
Unfortunately, despite some encouraging results, the Achilles’
heel of a rhythm control strategy remains arrhythmia recurrence.
Treatment directed at CHF, including angiotensin-converting
enzyme inhibitors, beta-blockers, and aldosterone antagonists,
helps to reduce the incidence of AF (4). However, safe and
effective antiarrhythmic therapy is lacking for patients with left
ventricular dysfunction. This includes amiodarone, which was
associated with excess mortality in the SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial) study among patients with
more advanced symptoms (5). Although preliminary results of
catheter ablation, either of AF itself or of atrioventricular nodal
ablation followed by biventricular pacing (6), are encouraging,
adequately powered randomized clinical trials are needed to
evaluate longer term safety and efficacy before any firm recommen-
dations can be made. However, in the context of CHF, the
evidence that it is better to be in sinus rhythm rather than AF is
compelling. We just need to identify interventions that are less
harmful or toxic than the problem.
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